Combipatch Related Published Studies
Well-designed clinical trials related to Combipatch (Estradiol / Norethindrone Transdermal)
Lipids and clotting factors during low dose transdermal estradiol/norethisterone use. [2005.04.11]
Effects of oral continuous and transdermal cyclic 17-beta estradiol and norethindrone acetate replacement therapy on platelet aggregation in postmenopausal women. [2002.08]
Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. [2002.04.25]
Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. [2002.03]
Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women. [2001.08]
The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. [2001.03]
Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. [2000.12]
Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. [2000.06]
Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17beta-estradiol and norethisterone. [2000.05]
Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. [2000.01]
A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. [1999.10]
A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. [1999.09]
The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. [1999.07]
Hemodynamic effects of transdermal estradiol alone and combined with norethisterone acetate. [1997.06]
Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. [1997]
[Prevention of postmenopausal osteoporosis: how effective is transdermal hormone substitution? (Continuous estradiol plus sequential oral norethisterone acetate)] [1995.08.26]
Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. [1995.04]
Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. [1994.07]
Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. [1993.11]
The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. [1990.03]
Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. [1989.09.23]
Well-designed clinical trials possibly related to Combipatch (Estradiol / Norethindrone Transdermal)
The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. [2005.10.16]
Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. [2005.01]
A comparison of the central effects of different progestins used in hormone replacement therapy. [2004.08.20]
Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. [2004.03]
Comparison of the effect of oral and transdermal hormone therapy on fasting and postmethionine homocysteine levels. [2004.01]
[The effect of transdermal hormone replacement therapy on vasomotor symptoms in perimenopausal women] [2004]
Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. [2003.12]
Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. [2003.05]
National differences in lipid response to postmenopausal hormone replacement therapy. [2002.08.30]
Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. [2002.07.25]
Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. [2002.05]
Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women. [2002.01]
Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. [2001.12]
Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study. [2001.11]
Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. [2001.04]
Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. [2000.12.29]
Plasma endothelin in postmenopausal women with type 2 diabetes mellitus and metabolic syndrome: a comparison of oral combined and transdermal oestrogen-only replacement therapy. [2000.10]
Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. [2000.01]
[Influence of hormone replacement therapy on the quality of life in postmenopausal women with hypertension] [2000]
Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. [1999.09]
Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. [1999.08]
Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. [1999.07]
Randomized comparison of oral and transdermal hormone replacement on carotid and uterine artery resistance to blood flow. [1998.10]
Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: the impact of body composition, maximal oxygen uptake and treatment with sex hormones. [1998.08]
The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. [1998.05]
Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy. [1998.01]
Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. [1997.12.15]
The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. [1997.11]
Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. [1997.03.21]
Different effects of oral and transdermal hormonal replacement on prostacyclin and thromboxane A2. [1997.01]
Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. [1997]
Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. [1996.12]
The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor. [1996.12]
Add-back therapy in the treatment of endometriosis: the European experience. [1996.10]
Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. [1996.10]
Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. [1996.05]
Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood--a beneficial effect on atherogenesis and thrombus formation? [1995.12]
Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. [1995.06]
Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. [1995.01]
Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. [1994.08]
Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. [1994.01]
Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. [1993.07]
Oral versus transdermal hormone replacement therapy. [1993]
Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. [1992.03]
Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. [1990.08.04]
Other research related to Combipatch (Estradiol / Norethindrone Transdermal)
Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. [2005.03]
A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. [2005]
The lipid and clinical effects of sequential transdermal estradiol and estradiol/norethisterone acetate in 674 women. [2003.10]
Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. [2002.10.25]
Effects of norethisterone acetate addition to estradiol in long term HRT. [2000.08.31]
Transdermal administration of estradiol and norethisterone: effect on the uterus and uterine arteries. [2000.03]
Visualization of percutaneous 3H-estradiol and 3H-norethindrone acetate transport across human epidermis as a function of time. [2000]
[Serum lipids in treatment with transdermal estradiol and oral norethisterone acetate] [1995.07]
Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women. [1994.03]
Hormone replacement therapy by the transdermal administration of oestradiol and norethisterone. [1994.03]
Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. [1992.12.28]
Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. [1992.11]
Endometrial effects of transdermal estradiol/norethisterone acetate. [1992.08]
Other possibly related research studies
Hormone replacement therapy and breast density changes. [2005.06]
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. [2005.09]
Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women's Health in the Lund Area study. [2004.09]
The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension. [2004.02]
[Changes in bone density in hemodialysed women treated with transdermal hormone replacement therapy] [2003.09]
Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. [2003.12.10]
Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. [2003.10]
Impact of different progestins on endometrial vascularisation of postmenopausal women. A retrospective image analysis-morphometric study. [2003.11.20]
The short-term effects of different regimens of hormone replacement therapy on left ventricular structure and performance in healthy postmenopausal women. A prospective, controlled echocardiographic study. [2003]
The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy. [2002.08.30]
Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. [2002.02]
Effects of HRT on serum levels of IGF-I in postmenopausal women. [2001.10.31]
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. [2001.05]
HRT dosing regimens: continuous versus cyclic-pros and cons. [2001.01]
The insulin-like growth factor-I system and hormone replacement therapy. [2001.02]
[Basic principles of hormone replacement therapy in the postmenopause] [2000.10]
Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. [2000.10]
Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. [2000.01]
Elevated levels of sE-selectin in post-menopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females. [1999.11]
Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status. [1999.06]
Transvaginal ultrasonography and endometrial histology in peri- and postmenopausal women on hormone replacement therapy. [1999.05]
The influence of norethisterone acetate on urinary urodilatin excretion in postmenopausal women. [1998]
|
